Bottom line
Is DLHAX a good fund? The bottom line
DLHAX is the Class A share class of Nomura Healthcare Fund, an actively managed health care sector mutual fund from Voya.
It charges 1.21% — about $121 a year on every $10,000 invested, more expensive than 70% of health care sector funds we track.
It returned +15.1% over one year, +6.2% a year over five years, +9.5% a year over ten (as of Dec 31, 2025, per its prospectus).
With $750 million in net assets and 108 holdings, its largest position is Ucb Sa (5.2%) and the top 10 make up 38.9% of the portfolio.
This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.
What stands out
- 5-year return beat 73% of category peers
What to watch
- Front-end sales load up to 5.75%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What DLHAX invests in
Nomura Healthcare Fund seeks maximum long-term capital growth through capital appreciation.
Under normal circumstances, Nomura Healthcare Fund ?will invest at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in the equity securities of healthcare companies (80% policy). For purposes of the Funds 80% policy, healthcare companies include those companies that develop, produce, or distribute products or services related to the healthcare or medical industries and derive a substantial portion of their sales from products and services in the healthcare industry. These products and services include, but are not limited to, pharmaceutical companies, biotechnology companies, medical device and supply companies, managed care companies, and healthcare information and service providers. The Fund invests in US and non-US companies across all market capitalizations. The Fund may invest up to 50% of its total assets in non-US companies. The Fund may…
From the fund's prospectus (filed Jul 29, 2026).
DLHAX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| DLHAX | +15.1% | +6.2% | +9.5% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What DLHAX costs
On a $10,000 investment, DLHAX's 1.21% expense ratio costs about $121 a year. The prospectus estimates $2,006 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
DLHAX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Ucb Sa UCB | 5.19% |
| 2 | Abbvie Inc ABBV | 4.19% |
| 3 | Eli Lilly & Company LLY | 4.16% |
| 4 | Regeneron Pharmaceuticals Inc REGN | 3.91% |
| 5 | Unitedhealth Group Inc UNH | 3.88% |
| 6 | Pfizer Inc PFE | 3.84% |
| 7 | Merck & Company Inc MRK | 3.68% |
| 8 | Gilead Sciences Inc GILD | 3.54% |
| 9 | Astrazeneca Plc AZN | 3.27% |
| 10 | Elevance Health Inc ELV | 3.25% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 38.9% of the fund. See all top 25 holdings and asset mix →